Publications by authors named "J Noack"

Article Synopsis
  • - SARS-CoV-2 has evolved to evade current monoclonal antibodies (mAbs), emphasizing the need for more resilient treatments that can neutralize various viral strains.
  • - A new human mAb called VIR-7229 has shown the ability to effectively neutralize multiple variants of SARS-CoV-2 and other related viruses, due to its unique targeting of a critical viral region known as the receptor-binding motif (RBM).
  • - VIR-7229 demonstrates a high resistance to the emergence of virus escape mutants, making it a promising candidate for future therapies against evolving coronaviruses.
View Article and Find Full Text PDF

Background: Narcissism has been implied as a putative risk factor for substance use disorders (SUDs). However, previous research did not disentangle the degree of substance use from substance-related problems, the symptoms of SUDs. This preregistered study addressed the open question whether grandiose and vulnerable narcissism and their constituent traits convey specific SUD risk, that is, explain substance-related problems beyond the degree of use.

View Article and Find Full Text PDF

The intestinal and respiratory tracts of healthy individuals serve as habitats for a diverse array of microorganisms, among which Klebsiella oxytoca holds significance as a causative agent in numerous community- and hospital-acquired infections, often manifesting in polymicrobial contexts. In specific circumstances, K. oxytoca, alongside other constituents of the gut microbiota, undergoes translocation to distinct physiological niches.

View Article and Find Full Text PDF

Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of vaccines and therapies remains poorly understood. Here we demonstrate that recently emerged BQ.

View Article and Find Full Text PDF
Article Synopsis
  • Chronic hepatitis B is a major global health issue, and co-infection with hepatitis delta virus (HDV) can worsen the disease; researchers are studying a monoclonal antibody (mAb) targeting hepatitis B virus (HBV) surface antigen (HBsAg) for potential treatment.
  • The monoclonal antibodies were developed from memory B cells of vaccinated individuals and tested in human liver-chimeric mice to observe their effectiveness against HBV and HDV in various stages of infection.
  • The chosen mAb, VIR-3434, showed strong neutralization capabilities against multiple HBV genotypes, significantly reducing virus levels in treated mice and is now being considered for clinical trials in humans with chronic hepatitis B or D.
View Article and Find Full Text PDF